CR20210514A - USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) - Google Patents

USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)

Info

Publication number
CR20210514A
CR20210514A CR20210514A CR20210514A CR20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A
Authority
CR
Costa Rica
Prior art keywords
reboxetine
narcolepsy
treat narcolepsy
cataplexy
treat
Prior art date
Application number
CR20210514A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20210514A publication Critical patent/CR20210514A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.
CR20210514A 2018-10-15 2019-10-14 USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) CR20210514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
CR20210514A true CR20210514A (es) 2021-11-12

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210514A CR20210514A (es) 2018-10-15 2019-10-14 USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)

Country Status (15)

Country Link
EP (1) EP3866768A4 (es)
JP (2) JP2022504975A (es)
KR (2) KR20240119194A (es)
CN (1) CN112888430A (es)
AU (3) AU2019361915A1 (es)
BR (1) BR112021007019A2 (es)
CL (1) CL2021000924A1 (es)
CO (1) CO2021004681A2 (es)
CR (1) CR20210514A (es)
EC (1) ECSP21031200A (es)
IL (2) IL282311B2 (es)
MX (2) MX2021004207A (es)
PE (1) PE20211199A1 (es)
SG (1) SG11202103588WA (es)
WO (1) WO2020081461A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
KR102893312B1 (ko) * 2021-10-19 2025-12-01 단국대학교 천안캠퍼스 산학협력단 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
WO2025207664A1 (en) * 2024-03-25 2025-10-02 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
CA2470636A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
JP2008501778A (ja) * 2004-06-09 2008-01-24 ファイザー・インク 疼痛の治療のためのレボキセチンの使用
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy

Also Published As

Publication number Publication date
MX2021004207A (es) 2021-08-11
CO2021004681A2 (es) 2021-06-21
CN112888430A (zh) 2021-06-01
WO2020081461A1 (en) 2020-04-23
NZ775057A (en) 2024-09-27
PE20211199A1 (es) 2021-07-01
EP3866768A1 (en) 2021-08-25
ECSP21031200A (es) 2021-05-31
AU2025201286A1 (en) 2025-03-13
CA3115983A1 (en) 2020-04-23
IL319177A (en) 2025-04-01
IL282311A (en) 2021-05-31
JP2025134749A (ja) 2025-09-17
BR112021007019A2 (pt) 2021-07-13
IL282311B1 (en) 2025-04-01
EP3866768A4 (en) 2022-01-05
IL282311B2 (en) 2025-08-01
KR20240119194A (ko) 2024-08-06
KR20210071046A (ko) 2021-06-15
JP2022504975A (ja) 2022-01-13
MX2025003477A (es) 2025-05-02
AU2019361915A1 (en) 2021-05-13
SG11202103588WA (en) 2021-05-28
CL2021000924A1 (es) 2021-09-03
AU2023200917A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
CL2023001949A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020)
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.
GT201700246A (es) Métodos y kits para tratar la depresión
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2018016332A (es) Quimioterapias de combinacion.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112019004540A2 (pt) método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina
MX2024012392A (es) Terapia combinada para el tratamiento del cancer